2023
Top advances of the year: Neuro‐oncology
Barden M, Omuro A. Top advances of the year: Neuro‐oncology. Cancer 2023, 129: 1467-1472. PMID: 36825454, DOI: 10.1002/cncr.34711.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBrain tumorsRecent phase 3 trialAnti-PD-1 immunotherapyCentral nervous system dysfunctionSingle-agent pembrolizumabHigh-dose chemotherapyPhase 3 trialPrimary CNS lymphomaStem cell transplantationLong-term outcomesLimited therapeutic optionsNervous system dysfunctionOngoing clinical trialsClinical trial landscapeDrug Administration approvalBRAF V600E mutationExcellent disease controlConsolidation therapyCNS lymphomaImproved survivalLeptomeningeal metastasesTherapeutic optionsCell transplantationCraniospinal irradiationPatient population
2022
Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment
Petersen G, Shatalov J, Verma T, Brim WR, Subramanian H, Brackett A, Bahar RC, Merkaj S, Zeevi T, Staib LH, Cui J, Omuro A, Bronen RA, Malhotra A, Aboian MS. Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment. American Journal Of Neuroradiology 2022, 43: 526-533. PMID: 35361577, PMCID: PMC8993193, DOI: 10.3174/ajnr.a7473.Peer-Reviewed Original ResearchConceptsMachine learning-based methodsLearning-based methodsBalanced data setData setsVector machine modelMachine learningClassification algorithmsMachine modelMachineAlgorithmData basesPrediction modelPromising resultsPrimary CNS lymphomaPrediction model study RiskRisk of biasRadiomic featuresClassifierSetCNS lymphomaWebLearningFeaturesQualitySystematic review
2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery 2017, 7: 1018-1029. PMID: 28619981, PMCID: PMC5581705, DOI: 10.1158/2159-8290.cd-17-0613.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAntineoplastic AgentsCARD Signaling Adaptor ProteinsCentral Nervous System NeoplasmsDrug Resistance, NeoplasmFemaleGuanylate CyclaseHumansLymphoma, B-CellMaleMaximum Tolerated DoseMiddle AgedMutationPiperidinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyrimidinesTreatment OutcomeYoung AdultConceptsPrimary central nervous system lymphomaBruton's tyrosine kinaseB-cell lymphomaRefractory B-cell lymphomaB cell antigen receptorCentral nervous system lymphomaRole of BTKDiffuse large B-cell lymphomaLarge B-cell lymphomaPhase I clinical trialClass BTK inhibitorIncomplete tumor responseNervous system lymphomaToll-like receptorsPI3K/mTORIbrutinib responseCNS lymphomaClinical responseComplete responseReceptor-associated proteinSystem lymphomaActivation markersTumor responseClinical trialsPCNSL cellsUpdated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2017, 35: 7515-7515. DOI: 10.1200/jco.2017.35.15_suppl.7515.Peer-Reviewed Original ResearchSecondary CNS lymphomaProgression-free survivalMedian progression-free survivalALT elevationCNS lymphomaAdverse eventsClinical responseGrade 4 adverse eventsRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsGrade 5 eventsManageable adverse eventsGrade 3 toxicityMedian overall survivalMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionSingle-agent ibrutinibUrinary tract infectionPrimary brain tumorsPromising clinical responsesMantle cell lymphomaCommon toxicitiesPhase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL).
Tun H, Johnston P, Grommes C, Reeder C, Omuro A, Menke D, Copland J, DeAngelis L, Witzig T. Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL). Journal Of Clinical Oncology 2017, 35: 7516-7516. DOI: 10.1200/jco.2017.35.15_suppl.7516.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaOverall response rateRefractory primary central nervous system lymphomaPhase I clinical trialPrimary vitreoretinal lymphomaMTD cohortStable diseaseClinical trialsCentral nervous system lymphomaTherapeutic activityDiffuse large B-cell lymphomaLarge B-cell lymphomaDose level 3Grade 3/4 toxicitiesNovel immunomodulatory agentsNervous system lymphomaCycles of treatmentDose escalation levelsCSF/blood ratioB-cell lymphomaExcellent CNS penetrationPO weeklyPomalidomide treatmentPseudo progressionCNS lymphoma
2016
Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology 2016, 19: 422-429. PMID: 27994065, PMCID: PMC5464299, DOI: 10.1093/neuonc/now238.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaProgression-free survivalOverall survivalCNS lymphomaPrognostic valueMRI characteristicsRandomized phase II trialEarly MRI evaluationFirst-line chemotherapyPatterns of relapsePhase II trialBaseline tumor sizeEnd of treatmentOverall tumor burdenPotential prognostic valueComplete response achievementHypersignal lesionsInfratentorial localizationProlonged OSII trialObjective responsePoor OSProspective trialMRI abnormalitiesTumor burdenSingle-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
Grommes C, Pastore A, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma. Blood 2016, 128: 783. DOI: 10.1182/blood.v128.22.783.783.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaProgression-free survivalSecondary CNS lymphomaMedian progression-free survivalHigh-dose methotrexate chemotherapyCentral nervous system lymphomaNervous system lymphomaAdverse eventsCNS lymphomaCombination armClinical responseMethotrexate chemotherapySystem lymphomaGrade 4 adverse eventsRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsManageable adverse eventsGrade 3 toxicityMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionUrinary tract infectionPrimary brain tumorsACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. ACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL). Neuro-Oncology 2016, 18: vi3-vi4. DOI: 10.1093/neuonc/now212.011.Peer-Reviewed Original ResearchSecondary CNS lymphomaCNS lymphomaPhase I/II studyRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsGrade 4 toxicityGrade 3 toxicityEnd-organ functionNormal end-organ functionSingle-agent ibrutinibPrimary brain tumorsPromising clinical responsesB-cell malignanciesCommon toxicitiesEligible patientsFungal encephalitisManageable toxicityMedian PFSMethotrexate regimensPrior therapySCNSL patientsClinical responseII study331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, Deangelis L. 331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Annals Of Oncology 2016, 27: vi105. DOI: 10.1093/annonc/mdw367.09.Peer-Reviewed Original ResearchPhase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Grommes C, Kaley T, Nolan C, Omuro A, Wolfe J, Mellinghoff I, DeAngelis L. Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2016, 34: 2046-2046. DOI: 10.1200/jco.2016.34.15_suppl.2046.Peer-Reviewed Original ResearchToxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) Conditioning
Scordo M, Bhatt V, Hsu M, Omuro A, Matasar M, DeAngelis L, Dahi P, Moskowitz C, Giralt S, Sauter C. Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) Conditioning. Transplantation And Cellular Therapy 2016, 22: s132-s133. DOI: 10.1016/j.bbmt.2015.11.465.Peer-Reviewed Original Research
2015
Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma
Christian G, Thomas K, Abdel-Wahab O, Omuro A, Ingo M, DeAngelis L. Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma. Blood 2015, 126: 3960. DOI: 10.1182/blood.v126.23.3960.3960.Peer-Reviewed Original ResearchRefractory primary CNS lymphomaPrimary CNS lymphomaSecondary CNS lymphomaDose level 2CNS lymphomaCommon grade 2 toxicityRecurrent primary CNS lymphomaRecurrent/refractory diseaseAggressive primary brain tumorCD20 antibody therapyCNS lymphoma patientsDose of ibrutinibGrade 4 toxicityPrior treatment regimensDose level 1Grade 2 toxicityGrade 3 toxicityMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionSingle-agent ibrutinibPhase I trialPrimary brain tumorsPromising clinical responsesAlternative therapeutic approachOutcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma
Bhatt V, Scordo M, Hsu M, Omuro A, DeAngelis L, Lin A, Matasar M, Dahi P, Moskowitz C, Giralt S, Sauter C. Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma. Blood 2015, 126: 1994. DOI: 10.1182/blood.v126.23.1994.1994.Peer-Reviewed Original ResearchHDT-ASCTIdeal body weightComplete remissionPartial remissionBody weightBusulfan/cyclophosphamide conditioningAutologous stem cell transplantationSecondary CNS lymphomaTransplant related mortalityHigh-dose therapyStem cell infusionStem cell transplantationBU AUCCyclophosphamide conditioningHCT-CIChemosensitive patientsFirst remissionPrior therapyRemission inductionCNS lymphomaFirst doseTarget AUCCell infusionMedian ageDosage adjustmentA Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning
Scordo M, Bhatt V, Hsu M, Omuro A, Matasar M, DeAngelis L, Dahi P, Moskowitz C, Giralt S, Sauter C. A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning. Blood 2015, 126: 4354. DOI: 10.1182/blood.v126.23.4354.4354.Peer-Reviewed Original ResearchNon-hematologic toxicitiesProgression-free survivalKaplan-Meier curvesSignificant grade 3HDT-ASCTMore grade 3Whole brain radiotherapyKarnofsky performance statusOverall survivalCNS lymphomaGrade 3Prior regimensHematopoietic cell transplant comorbidity indexAutologous stem cell transplantationHigh-dose therapyTransplant-related mortalityKaplan-Meier methodProspective clinical trialsRetrospective chart reviewStem cell transplantationGroups of ptsInitiation of conditioningYears of ageBU pharmacokineticsCTCAE 4.0Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio M, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy M, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet Haematology 2015, 2: e251-e259. PMID: 26688235, DOI: 10.1016/s2352-3026(15)00074-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCytarabineDacarbazineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineProspective StudiesQuality of LifeTemozolomideTreatment OutcomeVincristineConceptsPrimary CNS lymphomaProgression-free survivalKarnofsky Performance Scale scoreCytarabine groupPhase 2 trialCNS lymphomaPerformance Scale scoreTemozolomide groupElderly populationScale scoreMedian progression-free survivalPhase 2 trial designCommon grade 3Methotrexate-based regimensProphylactic G-CSFMedian overall survivalStandard chemotherapy regimenPoor prognosis patientsQuality of lifeChemotherapy regimenEfficacy endpointPrimary endpointPrognosis patientsElderly patientsImmunocompetent patients
2014
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide
Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH, Omuro AM. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leukemia & Lymphoma 2014, 56: 361-367. PMID: 24745937, DOI: 10.3109/10428194.2014.916800.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsCombined Modality TherapyCyclophosphamideDisease-Free SurvivalDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRemission InductionStem Cell TransplantationThiotepaTransplantation, AutologousTreatment OutcomeConceptsAutologous stem cell transplantProgression-free survivalHigh-dose chemotherapyStem cell transplantOverall survivalCell transplantSecondary central nervous system lymphomaRefractory diffuse large B-cell lymphomaMedian progression-free survivalCentral nervous system involvementCentral nervous system lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaTransplant-related mortalityNervous system involvementSecondary CNS lymphomaNervous system lymphomaStem cell harvestingB-cell lymphomaPotential treatment alternativeHDC-ASCTInduction chemotherapyRecurrent primaryCNS lymphomaComplete remissionMethotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2013
Primary leptomeningeal lymphoma
Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, DeAngelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma. Neurology 2013, 81: 1690-1696. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.Peer-Reviewed Original ResearchConceptsPrimary leptomeningeal lymphomaPrimary CNS lymphomaLeptomeningeal lymphomaCNS lymphomaLeptomeningeal enhancementCSF cytologyMedian Eastern Cooperative Oncology Group performance statusRare formEastern Cooperative Oncology Group performance statusInternational Primary CNS Lymphoma Collaborative GroupIntra-CSF chemotherapyMedian overall survivalFavorable clinical responseCases of lymphomaOptimal diagnostic evaluationGene rearrangement studiesB-cell lymphomaMultifocal symptomsSalvage treatmentSystemic chemotherapyClinical responseOverall survivalPerformance statusMedian ageSystemic involvementRituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal Of Clinical Oncology 2013, 31: 3971-3979. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/jco.2013.50.4910.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsChemoradiotherapyCranial IrradiationCytarabineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineRituximabTimeTreatment OutcomeVincristineConceptsProgression-free survivalMedian progression-free survivalMedian overall survivalPrimary CNS lymphomaOverall survivalR-MPVComplete responseCNS lymphomaMedian Karnofsky performance scoreMulticenter phase II studyLong-term disease controlEnd pointApparent diffusion coefficientExploratory end pointsKarnofsky performance scorePhase II studyPrimary end pointWhole brain radiotherapyLong-term outcomesWhite matter changesHigh response rateInduction chemotherapyStandard WBRTBrain radiotherapyII studyMulticenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study.
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire J, Benouaich Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, Sierra del Rio M, Gonzalez A, Houillier C, Tanguy M, Hoang-Xuan K. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study. Journal Of Clinical Oncology 2013, 31: 2032-2032. DOI: 10.1200/jco.2013.31.15_suppl.2032.Peer-Reviewed Original ResearchPrimary CNS lymphomaAbnormal liver function testsCycles of methotrexateProphylactic G-CSFWhole brain radiotherapyLiver function testsPhase II trialProspective multicenter studyBaseline cognitive impairmentQuality of lifePre-treatment characteristicsCommon toxicitiesCytarabine consolidationCNS lymphomaEfficacy endpointII trialPrimary endpointBrain radiotherapyElderly patientsObjective responseStandard chemotherapyCR rateFunction testsIntergroup studyMulticenter study